Weight-loss injections may cut breast cancer recurrence risk, study suggests

New research has raised the possibility that GLP-1 medications — drugs commonly prescribed for obesity and type 2 diabetes — could reduce the risk of breast cancer returning. The findings suggest that popular weight-loss injections, which have become increasingly widespread in recent years, may offer unexpected additional health benefits beyond their primary uses. However, researchers have cautioned that the current evidence remains observational rather than conclusive. GLP-1 receptor agonists, including well-known brands such as Ozempic and Wegovy, work by mimicking a natural hormone that regulates blood sugar and appetite. The class of drugs has become one of the most talked-about medical treatments globally, with demand far outstripping supply in many countries. Beyond their established benefits for managing weight and diabetes, scientists are now investigating whether these medications may help prevent cancer recurrence through mechanisms that are not yet fully understood. While the preliminary findings are encouraging, experts stress that further rigorous clinical trials are needed before doctors could confidently recommend these injections specifically for cancer prevention. The research represents an early-stage observation rather than definitive proof, and patients considering any new medication should consult their healthcare providers about potential benefits and risks tailored to their individual circumstances.

Source: Maariv — Original article in Hebrew.